Navigation Links
Research Reveals How Down Syndrome Shields Against Cancer
Date:5/20/2009

The findings might someday lead to better treatments, experts say

WEDNESDAY, May 20 (HealthDay News) -- A pair of genes may explain why people with Down syndrome are largely spared from many types of cancer, Boston researchers report.

The same genetic mechanism could be a potent target for new anti-cancer therapies, said the scientists, who published their findings online May 20 in Nature.

The pressing question now becomes, when will this happen? Or will it happen at all?

"Most universities around the country are very good at finding targets for intervention in cancer and this study suggests that these two genes, if they were overexpressed in a tumor, could shut down the tumor blood vessels," explained Dr. Arthur E. Frankel, holder of the Tula Lee Stone Chair in Cancer Research at the Texas A&M Health Science Center College of Medicine.

"The problem is that's not such a trivial thing to do," added Frankel, who is also director of the Cancer Research Institute and of hematology/oncology with Scott & White. "The observation is true, but it's not immediately obvious to me that it's going to help anyone in the short term."

Individuals with Down syndrome, the most common genetic cause of mental retardation, carry an extra copy of chromosome 21 and, therefore, extra copies of each of the 231 genes found on that chromosome.

And while people with Down syndrome have an increased risk of developing certain types of leukemia compared to the general population, they have just 10 percent the risk of dying from many common solid-tumor cancers, including breast, brain, pancreas, lung and colon cancers.

The phenomenon has long been a scientific riddle.

"In the 1950s at Harvard Medical School, one of the exam questions was, 'Why don't people with Down Syndrome get cancer?' The answer then was because they don't live long enough," said study senior author Sandra Ryeo
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3 4

Related medicine news :

1. PIPC Supports New Comparative Effectiveness Research (CER) Bill
2. CSI: Mayo Clinic Researchers Find Television Shows Inaccurately Portray Violent Crime
3. Prestigious award for outstanding primary-care researcher
4. University of Haifa research team awarded European Union research grant
5. Peter MacCallum Cancer Centre Expands Cancer Research Efforts with Automation Tool from Caliper Life Sciences
6. Research reveals molecular pathway behind invasive prostate cancers
7. Mayo Clinic Researchers Say Triple Drug Combination is Promising Option to Treat Metastatic HER2+ Breast Cancer
8. Two Targeted Therapies Likely Better Than One in Patients with Aggressive Lymphoma, Mayo Clinic Researchers Say
9. Mayo Clinic Researchers Say Agent Provides Treatment Option for Women with Hot Flashes
10. Drug That Targets Vasculature Growth Attacks Aggressive Thyroid Cancer, Mayo Clinic Researchers Report
11. $1.5 million awarded for palliative care research to improve care of seriously ill patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Research Reveals How Down Syndrome Shields Against Cancer
(Date:7/22/2014)... Cloud+MD Office 2.0 is a ... medical software and services, designed by experienced healthcare ... “Actionable Information” to help Independent Physician Practices, New ... Services optimize a wide range of business processes ... Noticeable Cost Reductions and Better Patient Care. ...
(Date:7/22/2014)... An Ideal Location , Narconon Arrowhead, ... naturally tranquil and very beautiful Arrowhead State Park, overlooking ... for both a rehabilitative setting, as well as a ... of fireworks. Launched over the waters of the ... in the lake, or from the nearby campgrounds and ...
(Date:7/22/2014)... 22, 2014 MonaVie announces today that ... Advisory Board (SAB). The addition of Macdonald will help ... current product development plans and necessary substantiation for research ... Macdonald has been with the company as its nutrition ... helping formulate MonaVie’s RVL and CORE ...
(Date:7/22/2014)... 22, 2014 Joining Conquer Paralysis Now as ... the next decade is Paralympic silver medalist and quadriplegic Jennifer ... became a quadriplegic from a spinal cord injury in 1998. ... a cure for paralysis. , “People define cure differently,” French ... something else. We have the image in our minds of ...
(Date:7/22/2014)... Beach, Florida (PRWEB) July 22, 2014 ... alcohol treatment center located in Pompano Beach, ... approval from the Joint Commission, an independent not-for-profit ... United States. Accreditation signifies that the quality programs ... Joint Commission standards for safety and performance. Ocean ...
Breaking Medicine News(10 mins):Health News:Cloud-MD Software will soon Receive MU2 Certification 2Health News:Narconon Arrowhead Holds Annual Firework Event 2Health News:Narconon Arrowhead Holds Annual Firework Event 3Health News:MonaVie Adds Nutritionist Mark Macdonald to Its Scientific Advisory Board 2Health News:MonaVie Adds Nutritionist Mark Macdonald to Its Scientific Advisory Board 3Health News:Paralympian Jen French Announced as Conquer Paralysis Now’s First Champion 2Health News:Florida Drug and Alcohol Addiction Treatment Center Receives Joint Commission Seal of Approval 2Health News:Florida Drug and Alcohol Addiction Treatment Center Receives Joint Commission Seal of Approval 3
... an effective vaccine against recurrent kidney cancers.// Kidney cancer ... causes about 12,000 deaths in the United States every ... 50s and 60s. Standard treatment involves removal of all ... however, kidney cancer does not respond well to subsequent ...
... shown that a chemotherapy regimen combining vinorelbine (Navelbine) and ... the treatment of hormone-refractory prostate cancer . Specialists say ... in their disease. , However researchers added ... regimen is planned. From a group of 66 patients ...
... Breast cancer survivors can now get up and ... // older women, reported higher body esteem and ... a new study. ,Researchers compared 40 ... sedentary women, all early-stage breast cancer survivors. Regular ...
... has shown that there may be a link of type ... blood has high amounts of iron.// ,In this ... with no history of diabetes, cardiovascular disease or cancer. 700 ... iron concentration of 109 nanograms/milliliter manifested with diabetes whereas ...
... placing a soft plastic tube or catheter into the ... Patients must undergo training for two weeks and ... from the comfort of their home. Hemodialysis patients can ... attached to a blood-cleaning machine at a dialysis center. ...
... replacement therapy among breast cancer survivors has been // stopped ... or new cancers. ,Swedish researchers embarked on the study ... therefore subject to the same menopausal symptoms as other women. ... five years. After the initial 345 women in the study ...
Cached Medicine News:Health News:A Combination Of Drugs Effective In The Treatment Of Hormone-Refractory Prostate Cancer 2
(Date:7/22/2014)... , July 22, 2014  Vernalis plc (LSE: ... of proof-of-concept (POC) for CCP-08, the third programme ... cough cold collaboration. Under this collaboration, POC requires ... successful human pilot comparative study against an immediate ... POC, Vernalis will make a milestone payment to ...
(Date:7/21/2014)... , July 21, 2014 McCord ... patent (U.S. Patent No. 8,796,315). This patent describes ... wound healing.  According to the inventor, Dr. McCord, ... who require wound healing, a composition of an ... derived from umbilical cord blood, such that the ...
(Date:7/21/2014)... , July 21, 2014  EHE International, the recognized ... a nationwide physician network, today announced that Dignity Health ... NV has been named an EHE-certified preventive ... Las Vegas region now have greater ... maintain their health. "EHE is proud ...
Breaking Medicine Technology:Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 2Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 3US Patent Office Grants McCord Research Endothelial Cell Treatment Patent 2EHE International Certifies Dignity Health Medical Group Nevada, LLC as Its Newest Partner 2
... LOS ANGELES & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 17, ... focused on,the discovery and development of novel, ... of AV-412, a novel,next generation oral tyrosine ... mutant and drug-resistant lung cancer tumor,models. The ...
... Decreased Tumor Blood Vessel,Density and Serum PSA ... and TUSTIN, Calif., April 17, 2007,/PRNewswire-FirstCall/ -- ... company developing targeted,monoclonal antibodies for the treatment ... today announced that preclinical data,presented at the ...
Cached Medicine Technology:AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 2AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 3AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 4Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 2Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 3Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 4Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 5
Open wire loops decrease the chance of interfering with instruments, Designed to retract the eyelid during ophthalmic microsurgery or minor office procedures...
For rotating nucleus during phacoemulsification, Also useful for dislocating the nucleus into the anterior chamber during extracapsular cataract extraction, 45, Blunt, Forked, 9.0mm from end...
... drape has two perforations which ... to various single or bilateral ... Refractive drape has two perforations ... adapts to various single or ...
Angled 45, 9mm from end, Longer design from bend to tip allows for easier placement of viscoelastic to all meridians, Dome shape, extra smooth tip...
Medicine Products: